Pralsetinib is another selective and strong inhibitor of RET that also showed clinical activity and safety in RET-altered thyroid cancers in a phase 1/2 study.513 Further studies are needed to confirm its performance in the clinic. This evidence concerns the gene RET and thyroid gland carcinoma.